MEDIUM confidence: 100% data completeness, but the composite (56) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-07-10.
Net insider -$29.3M over 180 days (0 open-market buys, 87 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
Working the DCF backward: holding the assumptions below, this is the free-cash-flow growth today's price implies over the next 10 years. It is a read on the price's embedded expectations — not a fair-value or target price.
The price implies FCF growth below the analyst consensus of 17.0%/yr (revenue basis).
Base free cash flow $956M (avg FY2023–FY2025; latest year $1.0B) · equity value $21.5B · levered FCF discounted at the cost of equity. Reverse DCF is illustrative, not advice.
| Metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $1.7B— | $1.9B+14.9% | $2.3B+20.2% | $2.9B+23.6% | $3.2B+10.6% |
| EPS (dil.) | $10.06— | $15.00+49.1% | $19.81+32.1% | $24.64+24.4% | $27.86+13.1% |
| Free Cash Flow | $477M— | $664M+39.0% | $748M+12.6% | $1.1B+44.5% | $1.0B-3.7% |
| Gross Margin | 92.7% | 92.4%-0.3pp | 88.9%-3.5pp | 89.2%+0.3pp | 87.9%-1.3pp |
| Operating Margin | 33.0% | 50.6%+17.6pp | 50.9%+0.3pp | 47.9%-3.1pp | 47.7%-0.2pp |
| Net Margin | 28.2% | 37.6%+9.3pp | 42.3%+4.8pp | 41.5%-0.8pp | 41.9%+0.4pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Buy-rated share 75% → 80% over ~3 months (+5pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Aug 2026 | $6.86 | $7.27 | +6.0% |
| May 2026 | $7.00 | $5.82 | -16.9% |
| Feb 2026 | $7.13 | $7.70 | +8.0% |
| Oct 2025 | $6.89 | $7.16 | +3.9% |
| Jul 2025 | $7.29 | $6.41 | -12.1% |
| Apr 2025 | $6.29 | $6.63 | +5.4% |
| Feb 2025 | $6.40 | $6.19 | -3.3% |
| Oct 2024 | $6.43 | $6.39 | -0.6% |
The QScore of 56 indicates a neutral outlook for United Therapeutics, driven by strong profitability and low risk, which scores high on categories such as return on equity near 20% and a beta of 0.6. However, the stock's value and growth scores are more subdued, with a P/E of 16.8 and revenue growth of 10.6%, while momentum is mixed, exhibiting strong 12-month returns of 68.1% but a recent 3-month decline of 12.6%. The long-term and short-term scores are relatively aligned, suggesting a consistent view of the stock's prospects.